Umbilical Cord Blood Banking Market

Global Market Study on UCB Banking: Asia-Pacific to Witness Highest Growth by 2020

Umbilical Cord Blood Banking Market Segmented By Leukemia, Bone Marrow Failure Syndrome, Metabolic/Storage Diseases, Lymphoma, Immune Deficiencies Application with Private UCB Banks and Public UCB Banks Storage Option

Report ID: PMRREP3043

Number of Pages: 127

Format: PPT*, PDF, EXCEL

Industry: Healthcare

Published Date: October-2014

Report Price

$4900*

Buy Now

Table of Content

Chapter 1. Preface

    1.1. Report Description

    1.2. Report Methodology

    1.3. Assumptions

Chapter 2. Market Synopsis

Chapter 3. Porter’s Five Forces Analysis

    3.1. Bargaining Power of Suppliers

    3.2. Bargaining Power of Buyers

    3.3. Threat of New Entrants

    3.4. Threat of Substitutes

    3.5. Intensity of Rivalry

Chapter 4. Industry overview

    4.1. Market Definition

    4.2. Market Drivers

        4.2.1. Increasing prevalence of chronic diseases enhances the market growth

        4.2.2. Emerging field of regenerative medicines boost the market growth

        4.2.3. Initiatives by various government associations have increased the importance of UCB

    4.3. Impact Analysis of Market Drivers

    4.4. Market Restraints

        4.4.1. Strict license and accreditation procedures impede the market growth

        4.4.2. High cord blood banking fee in private UCB banks

    4.5. Impact Analysis of Market Restraints

    4.6. Market Tends

        4.6.1. UCB is gaining popularity in allogeneic hematopoietic stem cell transplantation

        4.6.2. Umbilical cord tissue storage is gaining importance in UCB banking market

Chapter 5. Global Market Size and Forecast

Chapter 6. Market Size and Forecast by Therapeutic Application of UCB

    6.1. Leukemia

    6.2. Bone Marrow Failure Syndrome

    6.3. Metabolic/Storage Diseases

    6.4. Lymphoma

    6.5. Immune Deficiencies

Chapter 7. Market Size and Forecast by Storage Option

    7.1. Private UCB Banks

    7.2. Public UCB Banks

Chapter 8. Market Size and Forecast by Geography

    8.1. North America

        8.1.1. Scenario in the U.S.

            8.1.1.1. Legislations

        8.1.2. Scenario in Canada

    8.2. Europe

        8.2.1. Scenario in the U.K.

            8.2.1.1. Legislations

        8.2.2. Scenario in France

        8.2.3. Scenario in the Germany

        8.2.4. Scenario in Spain

        8.2.5. Scenario in Italy

        8.2.6. Scenario in Belgium

    8.3. Asia Pacific

        8.3.1. Scenario in China

        8.3.2. Scenario in India

        8.3.3. Scenario in Japan

        8.3.4. Scenario in Australia

        8.3.5. Scenario in Singapore

Chapter 9. Competitive Scenario

    9.1. Competitive Benchmarking

Chapter 10. Company Profiles

    10.1. Cord Blood Registry Systems, Inc.

        10.1.1. Company overview

        10.1.2. Products and services

        10.1.3. Financial performance

        10.1.4. Recent developments

    10.2. Cordlife Group Limited

        10.2.1. Company overview

        10.2.2. Products and services

        10.2.3. Financial performance

        10.2.4. Recent developments

    10.3. Cord Blood America, Inc.

        10.3.1. Company overview

        10.3.2. Products and services

        10.3.3. Financial performance

        10.3.4. Recent developments

    10.4. NeoStem, Inc.

        10.4.1. Company overview

        10.4.2. Products and services

        10.4.3. Financial performance

        10.4.4. Recent developments

    10.5. Cryo-Cell International, Inc.

        10.5.1. Company overview

        10.5.2. Products and services

        10.5.3. Financial performance

        10.5.4. Recent developments

    10.6. ViaCord

        10.6.1. Company overview

        10.6.2. Products and services

        10.6.3. Financial performance

        10.6.4. Recent developments

    10.7. Esperite N.V.

        10.7.1. Company overview

        10.7.2. Products and services

        10.7.3. Financial performance

        10.7.4. Recent developments

    10.8. StemCyte

        10.8.1. Company overview

        10.8.2. Products and services

        10.8.3. Financial performance

        10.8.4. Recent Developments

    10.9. Smart Cells International, Ltd.

        10.9.1. Company overview

        10.9.2. Products and services

        10.9.3. Financial performance

        10.9.4. Recent developments

    10.10. China Cord Blood Corporation

        10.10.1. Company overview

        10.10.2. Products and Services

        10.10.3. Financial performance

        10.10.4. Recent developments

Sample Report

Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

List Of Table

List of Tables

TABLE 1: Market Snapshot: Global market for UCB banking (2014 and 2020)

TABLE 2: Application of UCB in disease treatment

TABLE 3: Drivers for UCB banking market: Impact analysis

TABLE 4: Restraints for UCB banking market: Impact analysis

TABLE 5: Global market for UCB banking, by geography, 2010 – 2013 (USD million)

TABLE 6: Global market for UCB banking, by geography, 2014 – 2020 (USD million)

TABLE 7: Global market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 8: Global market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 9: Global market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 10: Global market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 11: Global market for therapeutic application of UCB in leukemia, by geography, 2010 – 2013 (USD million)

TABLE 12: Global market for therapeutic application of UCB in leukemia, by geography, 2014 – 2020 (USD million)

TABLE 13: Global market for therapeutic application of UCB in bone marrow failure syndrome, by geography, 2010 – 2013 (USD million)

TABLE 14: Global market for therapeutic application of UCB in bone marrow failure syndrome, by geography, 2014 – 2020 (USD million)

TABLE 15: Global market for therapeutic application of UCB in metabolic/storage diseases, by geography, 2010 – 2013 (USD million)

TABLE 16: Global market for therapeutic application of UCB in metabolic/storage diseases, by geography, 2014 – 2020 (USD million)

TABLE 17: Global market for therapeutic application of UCB in lymphoma, by geography, 2010 – 2013 (USD million)

TABLE 18: Global market for therapeutic application of UCB in lymphoma, by geography, 2014 – 2020 (USD million)

TABLE 19: Global market for therapeutic application of UCB in immune deficiencies, by geography, 2010 – 2013 (USD million)

TABLE 20: Global market for therapeutic application of UCB in immune deficiencies, by geography, 2014 – 2020 (USD million)

TABLE 21: Global market for private UCB banks, by geography, 2010 – 2013 (USD million)

TABLE 22: Global market for private UCB banks, by geography, 2014 – 2020 (USD million)

TABLE 23: Global market for public UCB banks, by geography, 2010 – 2013 (USD million)

TABLE 24: Global market for public UCB banks, by geography, 2014 – 2020 (USD million)

TABLE 25: The North American market for UCB banking, by country, 2010 – 2013 (USD million)

TABLE 26: The North American market for UCB banking, by country, 2014 – 2020 (USD million)

TABLE 27: The North American market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 28: The North American market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 29: The North American market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 30: The North American market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 31: The U.S. market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 32: The U.S. market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 33: Canada market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 34: Canada market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 35: The European market for UCB banking, by country, 2010 – 2013 (USD million)

TABLE 36: The European market for UCB banking, by country, 2014 – 2020 (USD million)

TABLE 37: The European market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 38: The European market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 39: The European market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 40: The European market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 41: The U.K. market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 42: The U.K. market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 43: French market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 44: French market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 45: German market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 46: German market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 47: Spanish market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 48: Spanish market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 49: Italian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 50: Italian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 51: Belgium market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 52: Belgium market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 53: Asia Pacific market for UCB banking, by country, 2010 – 2013 (USD million)

TABLE 54: Asia Pacific market for UCB banking, by country, 2014 – 2020 (USD million)

TABLE 55: Asia Pacific market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 56: Asia Pacific market for UCB banking, by therapeutic application, 2014 – 2020 (USD million)

TABLE 57: Asia Pacific market for UCB banking, by storage option, 2010 – 2013 (USD million)

TABLE 58: Asia Pacific market for UCB banking, by storage option, 2014 – 2020 (USD million)

TABLE 59: Chinese market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 60: Chinese market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 61: Indian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 62: Indian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 63: Japanese market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 64: Japanese market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 65: Australian market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 66: Australian market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 67: Singapore market for UCB banking, by therapeutic application of UCB, 2010 – 2013 (USD million)

TABLE 68: Singapore market for UCB banking, by therapeutic application of UCB, 2014 – 2020 (USD million)

TABLE 69: CBR major products and services categories

TABLE 70: Cordlife’s service categories

TABLE 71: CBAI’s product and services categories

TABLE 72: NeoStem’s major service categories

TABLE 73: Cryo-Cell’s service category

TABLE 74: ViaCord’s service categories

TABLE 75: Esperite’s major product and services categories

TABLE 76: StemCyte’s product and services categories

TABLE 77: Smart Cells’s service categories

TABLE 78: CCBC’s service category

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

- List Of Chart -

List of Figures

FIG. 1: UCB banking market: Porter\'s five forces analysis

FIG. 2: Steps involved in UCB collection and banking

FIG. 3: Major therapeutic applications of UCB

FIG. 4: Global UCB banking market share, by region, by value, 2013

FIG. 5: Global UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 6: Global UCB banking market share, by storage option, by value, 2013

FIG. 7: Global therapeutic application of UCB for leukemia market share, by region, by value, 2013

FIG. 8: Global therapeutic application of UCB for bone marrow failure syndrome market share, by region, by value, 2013

FIG. 9: Global therapeutic application of UCB in metabolic/storage diseases market share, by region, by value, 2013

FIG. 10: Global therapeutic application of UCB for lymphoma market share, by region, by value, 2013

FIG. 11: Global therapeutic application of UCB for immune deficiencies market share, by region, by value, 2013

FIG. 12: Global private UCB banks market share, by region, by value, 2013

FIG. 13: Global public UCB banks market share, by region, by value, 2013

FIG. 14: The North American UCB banking market share, by country, by value, 2013

FIG. 15: The North American UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 16: The North American UCB banking market share, by storage option, by value, 2013

FIG. 17: The U.S. UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 18: Canada UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 19: The European UCB banking market share, by country, by value, 2013

FIG. 20: The European UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 21: The European UCB banking market share, by storage option, by value, 2013

FIG. 22: The U.K. UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 23: French UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 24: German UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 25: Spanish UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 26: Italian UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 27: Belgium UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 28: Asia Pacific UCB banking market share, by country, by value, 2013

FIG. 29: Asia Pacific UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 30: Asia Pacific UCB banking market share, by storage option, by value, 2013

FIG. 31: Chinese UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 32: Indian UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 33: Japanese UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 34: Australian UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 35: Singapore UCB banking market share, by therapeutic application of UCB, by value, 2013

FIG. 36: Competitive landscape of UCB banking market

FIG. 37: Cordlife revenue and profit, 2012 – 2014 (USD million)

FIG. 38: CBAI revenue and net loss/income, 2011 – 2013 (USD million)

FIG. 39: NeoStem revenue and net loss/income, 2011 – 2013 (USD million)

FIG. 40: Cryo-Cell revenue and net loss/income, 2011 – 2013 (USD million)

FIG. 41: Esperite’s revenue and profit, 2011 – 2013 (USD million)

FIG. 42: CCBC’s revenue and net income, 2012 – 2014 (USD million)

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate